Avalon GloboCare Corp. (AVCO)
- GlobeNewswire
Avalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR™ Platform
Development of FLASH-CAR™ RNA-based cellular therapies includes utilization of Avalon’s new Point-of-Care Modular Autonomous Processing System (PMAPsys™)First FLASH-CAR™ candidate, AVA-011, on-track for clinical study in B-cell lymphoblastic leukemia and non-Hodgkin’s lymphoma patients FREEHOLD, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announces entering into a collaboration agreement with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center to advance the clinical development and production of Avalon’s next-generation, chimeric antigen receptor (CAR) therapies using FLASH CAR™ technology. The FLASH-CAR™ technology modifies patients’ T-cells and natural killer (NK) cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, and is being co-developed with the Company’s strategic partner, Arbele Limited. The adaptable FLASH-CAR™ platform can be used to create personalized cell therapies from a patient’s own cells, as well as “off-the-shelf” cell therapies from a universal donor. By avoiding viral vectors and complicated bio-processing procedures, the FLASH-CAR™ technology significantly reduces manufacturing costs and development times, resulting in more affordable and potentially breakthrough therapies for cancer patients. Avalon’s innovative FLASH-CAR™ technology can be used to generate universal cell therapies that may allow for widespread patient accessibility enabling broader commercial adoption compared to currently available CAR-T cell therapies. Avalon’s first FLASH-CAR™ platform candidate, AVA-011, targets both CD19 and CD22 tumor antigens on cancer cells and is in development for patients with relapsed/refractory B-cell lymphoblastic leukemia and non-Hodgkin’s lymphoma. In connection with the agreement, Avalon and the UPMC Hillman Cancer Center will co-develop and deploy Avalon’s new Point-of-Care Modular Autonomous Processing System (PMAPsys™) onsite at the UPMC Hillman Cancer Center, a National Cancer Institute (NCI)-designated comprehensive cancer center in the United States. Avalon and the UPMC Hillman Cancer Center will advance AVA-011 and other FLASH-CAR™ candidates using the PMAPsys™, a proprietary integrated, multi-functional laboratory platform intended to provide point-of-care process development, optimization, validation and manufacturing of clinical-grade products for cell and gene therapies at Good Manufacturing Practice (GMP) facilities. The implementation of Avalon’s multi-purpose and modular PMAPsys™ at the UPMC Hillman Cancer Center can also be used to enable and expedite onsite development of other clinical cell and gene therapy candidates. “I am thrilled to collaborate with Avalon on FLASH-CAR™cellular therapy candidates and to co-develop Avalon’s new PMAPsys™ platform,” said Dr. Yen-Michael Hsu, M.D., Ph.D., Director of the Immunologic Monitoring and Cellular Products Laboratory at the UPMC Hillman Cancer Center, as well as the principal investigator of this co-development program. “This cohesive, point-of-care facility could greatly enhance and improve process development, bio-production, validation and quality assessment of candidate cellular therapies. We believe this approach will lessen the burden in meeting regulatory requirements and reduce the overall manufacturing costs of clinical-grade products for cellular therapies.” “This is an important milestone in the clinical development and production of AVA-011 and other RNA-based FLASH-CAR™ candidates ahead of the start of our first-in-human clinical trials,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We are excited about our partnership on the PMAPsys™ with UPMC, which we believe will help accelerate the path to bringing our own and third-party cell therapies to market. We are working diligently to fast-track development and commercialization of our cellular immune-oncology therapeutic products, while providing the highest quality and safety standards for our patients.” About Avalon GloboCare Corp. Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com. For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite 3100Freehold, NJ 07728PR@Avalon-GloboCare.com Investor Relations:Crescendo Communications, LLCTel: (212) 671-1020 Ext. 304avco@crescendo-ir.com
- GlobeNewswire
Avalon GloboCare Expands Co-Development Program with MIT to Combat Cancer Metastasis
Dual cutting edge technology approach using CRISPR-based genome editing and QTY code-based truncated chemokine receptors Expansion of co-development program with Dr. Shuguang Zhang at the Massachusetts Institute of Technology (MIT) Media Lab to halt mobilization and spread of cancer FREEHOLD, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announces the expansion of its co-development research program with the Massachusetts Institute of Technology (MIT) to apply two leading technologies—CRISPR-based genome editing and QTY protein design—to potentially treat and prevent cancer metastasis. Metastasis—the spreading of cancer cells from the initial tumor site to surrounding tissues and distant organs—is responsible for the vast majority of cancer deaths. In an ongoing co-development research program, Avalon and the laboratory of Dr. Shuguang Zhang at MIT’s Media Lab have developed a novel approach to potentially block the signals that cancer cells require to metastasize in order to prevent cancer spread and death. Cancer cells mobilize and travel to other organs using the chemokine signaling network, made up of chemokine receptors on the surface of healthy cells and soluble ligands that bind these receptors. Dr. Zhang’s MIT laboratory is applying their novel QTY protein code technology to design truncated versions of receptors that can act as decoys, attracting cancer cells and preventing them from spreading to other organs. Avalon and MIT researchers are also working on a second approach—combining the QTY technology with the CRISPR-Cas9 gene editing system to re-program cell types that typically stimulate nearby cancer cells to spread, thereby deterring cancer metastasis. Avalon and MIT’s collaboration on the QTY code has already successfully generated a prototype device to soak up the excess chemokines and cytokines produced in the body that lead to a potentially fatal ‘cytokine storm,’ which can occur in patients with COVID-19 and in cancer patients being treated with CAR T-cell therapy. “I am delighted to expand this fruitful and important collaboration with Avalon with the goal of advancing our ability to treat and prevent cancer metastasis,” said Dr. Shuguang Zhang, Head of the Laboratory of Molecular Architecture at MIT’s Media Lab. “We have a talented team at MIT, including the enthusiastic support of MIT and Harvard’s Broad Institute professor, Dr. Feng Zhang, a pioneer and expert of CRISPR-based genomic editing in mammalian cells. Through our collaboration, we have been able to develop cutting edge technology that we believe has the potential to prevent the spread of cancer to other tissues, which ultimately leads to death.” “This new endeavor builds on our collaboration with MIT using the QTY code technology to develop innovative therapies for cancer metastasis,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “We are working diligently and remain dedicated to finding innovative ways of combatting cancer metastasis with the health of patients at the forefront of our minds.” About Avalon GloboCare Corp. Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com. For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite 3100Freehold, NJ 07728PR@Avalon-GloboCare.com Investor Relations:Crescendo Communications, LLCTel: (212) 671-1020 Ext. 304avco@crescendo-ir.com
- GlobeNewswire
Siyata Mobile Appoints Peter Goldstein as Chairman and Adds Seasoned Public Company Executive Luisa Ingargiola to Board of Directors
VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a leading global developer and provider of cellular communications solutions for enterprise customers, today announces the appointment of Peter Goldstein, currently a Siyata Board member, as the Chairman of its Board of Directors. In addition, Luisa Ingargiola, who has extensive experience on public company boards and in the capital markets, has been appointed to the Board of Directors effective as of the shareholders meeting on February 23, 2021. “Peter’s many years in working with emerging growth, publicly traded companies is paramount to our asking him to replace me as Chairman of the Board of Directors. I look forward to being able to rely on his diverse skill set and extensive leadership experience and will work closely with him to ensure that we continue to grow Siyata and maximize our shareholder value,” commented Marc Seelenfreund, CEO of Siyata Mobile. “We are also thrilled to welcome Luisa Ingargiola to our board replacing Brian Budd. Luisa has an extensive capital markets background and we are very fortunate to have her join us. In the meantime, I wish to thank Brian for his time on the Board and we wish him the best in his future endeavors.” Peter Goldstein is a seasoned executive and entrepreneur with more than 30 years as a C-suite executive for public and private companies. He is the founder, chairman, and chief executive officer of Grandview Capital Partners, Inc., a specialized boutique investment bank that provides innovative financial services to select entrepreneurial emerging growth companies. He also serves as managing director of Exchange Listing, LLC, which provides a myriad of services in the strategic planning and implementation of listing on a senior exchange, such as Nasdaq or NYSE, for private companies or those that are listed on alternate exchanges. Luisa Ingargiola currently serves as Chief Financial Officer of Avalon Globocare Corp. (Nasdaq: AVCO), a biotech healthcare company focused on cell-based therapeutic and diagnostic technologies for cancer and other diseases. She also serves on several boards of publicly traded companies including ElectraMeccanica Vehicles Corp (Nasdaq: SOLO) and AgEagle Aerial Systems, Inc. (NYSE American: UAVS), where she is the audit committee chair. About Siyata Mobile Siyata Mobile Inc. is a Business-to-Business (B2B) global vendor of next generation Push-To-Talk over Cellular (PoC) devices and cellular booster systems. Its portfolio of in-vehicle and rugged smartphones enable first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to improve communication, increase situational awareness and save lives. Its portfolio of enterprise cellular booster systems enables first responders and enterprise workers to amplify its cellular signal in remote areas, inside structural buildings where signals are weak and within vehicles for maximum cellular signal strength possible. Siyata’s common shares trade on the Nasdaq under the symbol “SYTA” and its warrants under the symbol “SYTAW”. Visit siyatamobile.com and unidencellular.com/ to learn more. Twitter: @siyatamobileLinkedin: https://www.linkedin.com/company/siyata-mobile/ On Behalf of the Board, Marc Seelenfreund, President and CEO Investor Relations:Kin Communications1-866-684-6730SYTA@kincommunications.com Forward Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Siyata is using forward-looking statements in this press release when it discusses the expected timing of the fulfillment of the purchase order and the belief that with carrier approvals, sales teams and multiple large scale distribution channels secured throughout 2020, that Siyata is strongly positioned to benefit from the generational shift of enterprises and first responders transitioning from land mobile radio to cellular networks for their communication. Because such statements deal with future events and are based on Siyata’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Siyata’s filings with the Securities and Exchange Commission (“SEC”), and in any subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.
